phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.24411/2588-0527-2019-10035phgenomics-144Research ArticleПЕРСПЕКТИВЫ ФАРМАКОГЕНЕТИКИPERSPECTIVE OF PHARMACOGENETICSФармакогенетика фармакодинамических мишеней действия статиновPharmacogenetics of pharmacodynamic targets of statin actionЛеоноваМ. В.LeonovaM. V.

Леонова Марина Васильевна – д. м. н, профессор, член-корреспондент РАЕН, клинический фармаколог, Член Межрегиональной общественной организации Ассоциация клинических фармакологов России. SPIN-код: 3281-7884

Москва

Leonova Marina – DM, professor, Corresponding Member of RAEN, clinical pharmacologist, member of Interregional public organization Association of clinical pharmacologists of Russia. SPIN-code: 3281-7884

Moscow

anti23@mail.ruМОО «Ассоциация клинических фармакологов»РоссияAssociation of clinical pharmacologistsRussian Federation20192303202001311Copyright © Леонова М.В., 20192019Леонова М.В.Leonova M.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/144

Представлен научный обзор современных данных по влиянию генетического полиморфизма наиболее изученных и доказанных геном-кандидатов фармакологических мишеней, задействованных в липидснижающем и клиническом эффекте статинов. Рассмотрены такие гены-кандидаты, как АРОЕ, СЕТР, HMGCR, ЛПНП-рецептор, LPA, KIF6 и показаны результаты исследований и метаанализов, подтверждающих их влияние на эффективность статинов, преимущественно уровень ЛПНП и ЛПВП. Полиморфизм этих генов способствует вариабельности гиполипидемического эффекта в реальной клинической практике и имеет межэтнические особенности. Генотипирование по маркерам-предикторам фармакодинамической эффективности статинов может представлять основу персонализированной медицины.

A scientific review of current data on the effect of the genetic polymorphism of the most studied and proven candidate genome pharmacological targets involved in the lipid-lowering and clinical effect of statins is presented. Such candidate genes as APOE, СЕТР, HMGCR, LDL receptor, LPA, and KIF6 are examined and the results of studies and meta-analyzes confirming their effect on statin efficacy, mainly LDL and HDL levels are shown. Polymorphism of these genes promotes variability of hypolipidemic effect in real clinical practice and has interethnic features. Genotyping by predictive markers of pharmacodynamic effectiveness of statins can represent the basis of personalized medicine.

генетический полиморфизмфармакодинакикастатинылипидснижающий эффектЛПНПgenetic polymorphismpharmacodynamicsstatinslipid-lowering effectLDLReferencesCholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifucation therapy and attainment in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005;21:1389–1399. DOI: 10.1185/030079905X59139Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifucation therapy and attainment in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005;21:1389–1399. DOI: 10.1185/030079905X59139Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008; 24(7):19511963. DOI:10.1185/03007990802138731Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008; 24(7):19511963. DOI:10.1185/03007990802138731Сусеков А.В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце. – 2006. – № 6. – С. 324–328.Susekov AV, Zubarevа MYu, Deev AD, et al. Main results Moscow research on statins (Moscow Statin Survey, MSS). Serdtse. 2006;6:324–328. (In Russ).Zineh I. Pharmacogenetics of Response to Statins. Curr Аtheroscler rep. 2007;9(3):187–194.Zineh I. Pharmacogenetics of Response to Statins. Curr Аtheroscler rep. 2007;9(3):187–194.Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 2011;34:1–19. DOI: 0114-5916/11/0001-0001/$49.95/0Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 2011;34:1–19. DOI: 0114-5916/11/0001-0001/$49.95/0Duman I. Role of Pharmacogenetics on Response to Statins: A Genotype-based Approach to Statin Therapy Outcome. Journal of Cardiology and Therapy. 2014;1(6):111–120. DOI:10.6051/j.issn.2309-6861.2014.01.35Duman I. Role of Pharmacogenetics on Response to Statins: A Genotype-based Approach to Statin Therapy Outcome. Journal of Cardiology and Therapy. 2014;1(6):111–120. DOI:10.6051/j.issn.2309-6861.2014.01.35Nieminen T, Kähönen M, Viiri LE, et al. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics. 2008;9:1475–1486. DOI: 10.2217/14622416.9.10.1475Nieminen T, Kähönen M, Viiri LE, et al. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics. 2008;9:1475–1486. DOI: 10.2217/14622416.9.10.1475Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis. 2011;10:48. DOI: 10.1186/1476-511X-10-48Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis. 2011;10:48. DOI: 10.1186/1476-511X-10-48Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154. DOI: 10.3389/fnagi.2014.00154Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154. DOI: 10.3389/fnagi.2014.00154Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004;141:137–147. DOI: 10.7326/0003-4819-141-2-200407200-00013Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004;141:137–147. DOI: 10.7326/0003-4819-141-2-200407200-00013Yin YW, Sun QQ, Zhang BB, et al. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Chinese population: evidence from a meta-analysis of 40 studies. PLoS One/ 2013;8:e66924. DOI: 10.1371/journal.pone.0066924Yin YW, Sun QQ, Zhang BB, et al. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Chinese population: evidence from a meta-analysis of 40 studies. PLoS One/ 2013;8:e66924. DOI: 10.1371/journal.pone.0066924Hubacek JA, Vrablik M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact. 2011;26(1):13–20. DOI: 10.1515/DMDI.2011.107Hubacek JA, Vrablik M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact. 2011;26(1):13–20. DOI: 10.1515/DMDI.2011.107Ballantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progressionregression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000;36(5):1572–1578. DOI: 10.1016/S0735-1097(00)00918-9Ballantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progressionregression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000;36(5):1572–1578. DOI: 10.1016/S0735-1097(00)00918-9Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1): 183–193.Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1): 183–193.Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. 2008;18:279–287. DOI: 10.1097/FPC.0b013e3282f60aadDonnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. 2008;18:279–287. DOI: 10.1097/FPC.0b013e3282f60aadMega JL, Morrow DA, Brown A, et al. Identification of Genetic Variants Associated With Response to Statin Therapy. Arterioscler Thromb Vasc Biol. 2009;29:1310–1315. DOI: 10.1161/ATVBAHA.109.188474Mega JL, Morrow DA, Brown A, et al. Identification of Genetic Variants Associated With Response to Statin Therapy. Arterioscler Thromb Vasc Biol. 2009;29:1310–1315. DOI: 10.1161/ATVBAHA.109.188474Thompson JF, Hyde CL, Wood LS, et al. Comprehensive wholegenome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ. Cardiovasc. Genet. 2009;2:173–181. DOI: 10.1161/CIRCGENETICS.108.818062Thompson JF, Hyde CL, Wood LS, et al. Comprehensive wholegenome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ. Cardiovasc. Genet. 2009;2:173–181. DOI: 10.1161/CIRCGENETICS.108.818062Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection study. Eur. Heart J. 2013;34:982–992. DOI: 10.1093/eurheartj/ehs344Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection study. Eur. Heart J. 2013;34:982–992. DOI: 10.1093/eurheartj/ehs344Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 2006;61:327–331. DOI: 10.2143/AC.61.3.2014836Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 2006;61:327–331. DOI: 10.2143/AC.61.3.2014836Maitland-van der Zee AH, Stricker BH, Klungel OH, et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics. 2003;13:219–223. DOI: 10.1097/01.fpc.0000054080.64000.f1Maitland-van der Zee AH, Stricker BH, Klungel OH, et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics. 2003;13:219–223. DOI: 10.1097/01.fpc.0000054080.64000.f1Zintzaras E, Kitsios GD, Triposkiadis F, et al. APOE gene polymorphisms and response to statin therapy among APOE genetic variants. Pharmacogenomics J. 2009;9:248–257. DOI: 10.1038/tpj.2009.25Zintzaras E, Kitsios GD, Triposkiadis F, et al. APOE gene polymorphisms and response to statin therapy among APOE genetic variants. Pharmacogenomics J. 2009;9:248–257. DOI: 10.1038/tpj.2009.25Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101(12):1366–1371. DOI: 10.1161/01.CIR.101.12.1366Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101(12):1366–1371. DOI: 10.1161/01.CIR.101.12.1366Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed. Pharmacother. 2011;65:597–603. DOI:10.1016/j.biopha.2011.04.003Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed. Pharmacother. 2011;65:597–603. DOI:10.1016/j.biopha.2011.04.003Ordovas JM. Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): Should we be measuring them? Clin. Chem. Lab. Med. 2000;38:945–949. DOI: 10.1515/CCLM.2000.139Ordovas JM. Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): Should we be measuring them? Clin. Chem. Lab. Med. 2000;38:945–949. DOI: 10.1515/CCLM.2000.139Tsai MY, Johnson C, Kaoc WHL, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200:359–367. DOI:10.1016/j.atherosclerosis.2007.12.038Tsai MY, Johnson C, Kaoc WHL, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200:359–367. DOI:10.1016/j.atherosclerosis.2007.12.038Cao M, Zhou ZW, Fang BJ, et al. Meta-analysis of cholesteryl ester transfer protein TaqIB polymorphism and risk of myocardial infarction. Medicine (Baltimore). 2014;93(26):e160. DOI: 10.1097/MD.0000000000000160Cao M, Zhou ZW, Fang BJ, et al. Meta-analysis of cholesteryl ester transfer protein TaqIB polymorphism and risk of myocardial infarction. Medicine (Baltimore). 2014;93(26):e160. DOI: 10.1097/MD.0000000000000160Guo SX, Yao MH, Ding YS, et al. Associations of Cholesteryl Ester Transfer Protein TaqIB Polymorphism with the Composite Ischemic Cardiovascular Disease Risk and HDL-C Concentrations: A Meta-Analysis. Int J Environ Res Public Health. 2016;13(9):882–901. DOI: 10.3390/ijerph13090882Guo SX, Yao MH, Ding YS, et al. Associations of Cholesteryl Ester Transfer Protein TaqIB Polymorphism with the Composite Ischemic Cardiovascular Disease Risk and HDL-C Concentrations: A Meta-Analysis. Int J Environ Res Public Health. 2016;13(9):882–901. DOI: 10.3390/ijerph13090882van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 2003; 26:1216–1223. DOI: 10.2337/diacare.26.4.1216van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 2003; 26:1216–1223. DOI: 10.2337/diacare.26.4.1216Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta. 2005;362:182–188. DOI: 10.1016/j.cccn.2005.06.005Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta. 2005;362:182–188. DOI: 10.1016/j.cccn.2005.06.005Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003;146(6):1007–1014. DOI: 10.1016/S0002-8703(03)00501-5Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003;146(6):1007–1014. DOI: 10.1016/S0002-8703(03)00501-5Li Q, Huang P, He Q-C, et al. Association between the CETP polymorphisms and the risk of Alzheimer’s disease, carotid atherosclerosis, longevity, and the efficacy of statin therapy. Neurobiology of Aging. 2014;35:1513.e13-1513.e23. DOI:10.1016/j.neurobiolaging.2013.12.032Li Q, Huang P, He Q-C, et al. Association between the CETP polymorphisms and the risk of Alzheimer’s disease, carotid atherosclerosis, longevity, and the efficacy of statin therapy. Neurobiology of Aging. 2014;35:1513.e13-1513.e23. DOI:10.1016/j.neurobiolaging.2013.12.032McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008;22(4):321–338. DOI: 10.1007/s10557-008-6113-zMcTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008;22(4):321–338. DOI: 10.1007/s10557-008-6113-zKuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338(2):86–93. DOI: 10.1056/NEJM199801083380203Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338(2):86–93. DOI: 10.1056/NEJM199801083380203Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur. Heart J. 2008;29(22):2792–2799. DOI: 10.1093/eurheartj/ehn465Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur. Heart J. 2008;29(22):2792–2799. DOI: 10.1093/eurheartj/ehn465Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111(3):278–287. DOI: 10.1161/01.CIR.0000153341.46271.40Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111(3):278–287. DOI: 10.1161/01.CIR.0000153341.46271.40Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821–2827. DOI: 10.1001/jama.291.23.2821Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821–2827. DOI: 10.1001/jama.291.23.2821Donnelly LA, Doney AS, Dannfald J, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics. 2008;18:1021–1026. DOI: 10.1097/FPC.0b013e3283106071Donnelly LA, Doney AS, Dannfald J, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics. 2008;18:1021–1026. DOI: 10.1097/FPC.0b013e3283106071Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008;117:1537–1544. DOI: 10.1161/CIRCULATIONAHA.107.708388Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008;117:1537–1544. DOI: 10.1161/CIRCULATIONAHA.107.708388Polisecki E, Muallem H, Maeda N, et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigatorset al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008;200:109–114. DOI: 10.1016/j.atherosclerosis.2007.12.004Polisecki E, Muallem H, Maeda N, et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigatorset al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008;200:109–114. DOI: 10.1016/j.atherosclerosis.2007.12.004Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. DOI: 10.1001/jama.2009.1063Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. DOI: 10.1001/jama.2009.1063Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases. Biomed. Res. Int. 2013;2013:650989. DOI: 10.1155/2013/650989Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases. Biomed. Res. Int. 2013;2013:650989. DOI: 10.1155/2013/650989Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 2012;53:1000–1011. DOI: 10.1194/jlr.P021113Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 2012;53:1000–1011. DOI: 10.1194/jlr.P021113Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 2012;5: 257–264. DOI: 10.1161/CIRCGENETICS.111.961144Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 2012;5: 257–264. DOI: 10.1161/CIRCGENETICS.111.961144Donnelly LA, van Zuydam NR, Zhou K, et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics. 2013;23(10):518–525. DOI: 10.1097/FPC.0b013e3283642fd6Donnelly LA, van Zuydam NR, Zhou K, et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics. 2013;23(10):518–525. DOI: 10.1097/FPC.0b013e3283642fd6Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin Chem Lab Med. 2005;43:793–801.Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin Chem Lab Med. 2005;43:793–801.Assimes TL, Hólm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56:1552–1563. DOI: 10.1016/j.jacc.2010.06.022Assimes TL, Hólm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56:1552–1563. DOI: 10.1016/j.jacc.2010.06.022Ruiz-Ramos D, Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, López-Narváez ML, González-Castro TB, Torres-Hernández ME, BañosGonzález MA. The Trp719Arg polymorphism of the KIF6 gene and coronary heart disease risk: systematic review and meta-analysis. Hereditas. 2015;152:3. DOI: 10.1186/s41065-015-0004-7Ruiz-Ramos D, Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, López-Narváez ML, González-Castro TB, Torres-Hernández ME, BañosGonzález MA. The Trp719Arg polymorphism of the KIF6 gene and coronary heart disease risk: systematic review and meta-analysis. Hereditas. 2015;152:3. DOI: 10.1186/s41065-015-0004-7Peng P, Lian J, Huang RS, et al. Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One. 2012;7(12):e50126. DOI: 10.1371/journal.pone.0050126Peng P, Lian J, Huang RS, et al. Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One. 2012;7(12):e50126. DOI: 10.1371/journal.pone.0050126Li Y, Iakoubova OA, Shiffman D, et al. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am J Cardiol. 2010;106(7):994–998. DOI: 10.1016/j.amjcard.2010.05.033Li Y, Iakoubova OA, Shiffman D, et al. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am J Cardiol. 2010;106(7):994–998. DOI: 10.1016/j.amjcard.2010.05.033Leusink M, Onland-Moret NC, de Bakker PIW, et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17(2):163–180. DOI: 10.2217/pgs.15.158Leusink M, Onland-Moret NC, de Bakker PIW, et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17(2):163–180. DOI: 10.2217/pgs.15.158Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic metaanalysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. DOI: 10.1038/ncomms6068Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic metaanalysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. DOI: 10.1038/ncomms6068Postmus I, Warren HR, Trompet S, et al. Meta-analysis of genomewide association studies of HDL cholesterol response to statins. J Med Genet. 2016;53(12):835–845. DOI: 10.1136/jmedgenet-2016-103966Postmus I, Warren HR, Trompet S, et al. Meta-analysis of genomewide association studies of HDL cholesterol response to statins. J Med Genet. 2016;53(12):835–845. DOI: 10.1136/jmedgenet-2016-103966

The authors declare that there are no conflicts of interest present.